Fenbendazole is an antihelminthic drug that has been shown to have some cytotoxic properties. It has a wide range of pharmacological actions and is often used in combination with other drugs in the treatment of parasitic diseases. This is because it can help in improving the effectiveness of some other treatments. For example, it has been found to increase the effectiveness of cancer therapy by lowering p53 levels in cancer cells and by promoting normalization of the DNA repair system. It also has a powerful inflammatory effect that can destroy cancer cells. This is why it is often combined with curcumin in cancer therapy supplements.
These two substances have been shown to work together to produce significant inhibition of tumor growth. The researchers involved in this study analyzed several different combinations of vitamins, fenbendazole and curcumin to find the best results. They found that a combination of vitamins and fenbendazole was the most effective for inhibiting tumor growth. The vitamin and fenbendazole combination worked well on all types of tumors, but the most dramatic results were seen when it was used on ovarian and breast cancers. The research was conducted in mice and human cellular cultures.
The experiments involved dividing EMT6 mammary carcinoma cells into control groups and groups that received either three daily injections of fenbendazole or 10 Gy of radiation. The irradiated groups were treated in the same way as the nonirradiated groups, with the exception that a fenbendazole group was added to each. The irradiated and control groups were compared for growth of the tumors, as well as for the presence of lung metastases.
The effects of fenbendazole were evaluated separately in cell culture and as a single agent, as well as in combination with radiation and the taxanes. Febendazole did not affect the sensitivity of EMT6 cells to radiation or docetaxel in vitro. However, fenbendazole in combination with docetaxel and radiation significantly increased the antineoplastic effects of these agents.
For the in vivo studies, tumors were implanted subcutaneously on the flanks of SCID mice and grown until they reached a calculated volume of 1500 mm3. The animals were then divided into groups that received a fenbendazole-containing antihelminthic diet, a vitamin-only diet, or both a vitamin-only diet and fenbendazole. Tumor volumes were measured by caliper at 4-d intervals and the data were compared between the groups. The vitamin-only and fenbendazole groups both showed significantly decreased tumor growth. The vitamin-fenbendazole group was slightly less successful in reducing tumor growth than the vitamin-only diet. This may be because the vitamin concentrations in the diet deteriorate over time, and the vitamin-fenbendazole diet was near expiration at the beginning of this study.
The fenbendazole groups were then anesthetized with 100 mg/kg of ketamine and 10 mg/kg xylazine, and the tumors were irradiated locally on a Siemens Stabilipan (Malvern, PA). At the end of the study, the mice were killed and examined for signs of local invasion and lymph node metastases.sanare lab fenbendazole
